Loading data
SURGNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 56.96 m USD | 60.88 m USD | 137.14 m USD | 121.54 m USD | 51.06 m USD |
| Cost of revenue | 67.55 m USD | 75.21 m USD | 101.5 m USD | 108.07 m USD | 44.89 m USD |
| Selling, general and administrative expense | 20.07 m USD | 27.46 m USD | 16.78 m USD | 12.84 m USD | 12.16 m USD |
| Operating profit | -34.14 m USD | -43.46 m USD | 18.87 m USD | 633.79 k USD | -5.99 m USD |
| Interest expense | — | — | — | 400 k USD | — |
| Profit before tax | -36.07 m USD | -43.07 m USD | 18.38 m USD | -553.23 k USD | — |
| Income tax expense | — | 2.87 m USD | -2.27 m USD | — | — |
| Net income (reported basis) | -36.07 m USD | -45.73 m USD | 20.62 m USD | -680.76 k USD | -13.53 m USD |
| Net income attributable to common shareholders | -36.07 m USD | -45.73 m USD | 20.62 m USD | -680.76 k USD | — |
| Basic earnings per share | -1.8 USD/share | -2.39 USD/share | 1.45 USD/share | -0.05 USD/share | -3.09 USD/share |
| Diluted earnings per share | -1.8 USD/share | -2.39 USD/share | 1.38 USD/share | -0.05 USD/share | — |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.